News Focus
News Focus
Followers 65
Posts 27583
Boards Moderated 0
Alias Born 11/23/2016

Re: Amatuer17 post# 256606

Sunday, 06/28/2020 7:49:45 AM

Sunday, June 28, 2020 7:49:45 AM

Post# of 515611
The scenario I have in mind is that about 25% of patients across treatment arms may respond well, which is unlikely to yield stat sig topline results.

In this scenario, which imo is likely the working assumption for Anavex and their precision medicine approach, they cannot afford to PR topline results naked.

Instead the PR story will be about precision medicine showing that the data driven hypothesis has proven true and how that will significantly increases the chances if success in the next trials.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News